4/A: Protara Therapeutics CEO Amends Filing to Correctly Report Beneficial Ownership
SEC Form 4/A
Jesse Shefferman, CEO and President of Protara Therapeutics, files an amended Form 4 to correct a previously misreported amount of securities beneficially owned.
Summary
- Jesse Shefferman, the CEO and President of Protara Therapeutics, filed an amended Form 4 on March 28, 2025.
- This amendment corrects a previous filing from January 28, 2025, which inadvertently misreported the amount of securities beneficially owned by Shefferman following a reported transaction.
- The corrected filing indicates that Shefferman beneficially owns 978,553 shares of Protara Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing amendment, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. Amendments are not uncommon and can occur for various reasons, including administrative errors.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of Earliest Transaction |
| 01/28/2025 | Date of Original Filed Form 4 |
| 03/28/2025 | Date of Amended Form 4 Filing |
Keywords
Form 4, amendment, beneficial ownership, Protara Therapeutics, Jesse Shefferman, securities, TARA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.